DA
IMDX

DCF Advisers’s Insight Molecular Diagnostics IMDX Stock Holding History

DCF Advisers’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,257
Closed -$23K – 87
2022
Q2 		$23K Hold
1,257
– – 0.01% 76
2022
Q1 		$37K Buy
1,257
+650
+107% +$20.8K 0.02% 68
2021
Q4 		$26K Hold
607
– – 0.01% 73
2021
Q3 		$43K Buy
+607
New +$55.8K 0.02% 81

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

DCF Advisers's IMDX Position: Q3 2022 in Review

DCF Advisers sold out of Insight Molecular Diagnostics (IMDX) in Q3 2022, closing a stake of 1,257 shares — an estimated $23K sold.

DCF Advisers first reported a position in IMDX in Q3 2021 and held it in 4 quarters. The position peaked at $43K in Q3 2021. 65 funds tracked by Wall St. Rank hold IMDX as of Q3 2022.

  • DCF Advisers reported no remaining Insight Molecular Diagnostics position as of Q3 2022 after selling out during the quarter.
  • DCF Advisers sold 1,257 Insight Molecular Diagnostics shares in Q3 2022, an estimated $23K.
  • DCF Advisers first reported a position in Insight Molecular Diagnostics in Q3 2021 and held it in 4 quarters.
  • DCF Advisers's Insight Molecular Diagnostics position peaked at $43K in Q3 2021.
  • 65 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2022.

Based on DCF Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.